Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Open season?

The EMA's decision to post minutes of CHMP meetings is another step forward for industry transparency

Just as pharma's frontrunners come into view with proposals to substantially advance the clinical trial data debate the EMA moves to address some of its own transparency issues.

The Agency has, for the first time, scraped away some opacity from its inner workings and begun publishing meeting minutes for its Committee for Medicinal Products for Human Use (CHMP). Given that the CHMP, as we well know, issues advice on which products to approve, the move could offer an intriguing glimpse into a previously closed world.

However, the first minutes published leave a little to be desired. Information considered “commercially confidential or sensitive” is “therefore not disclosed”, along with certain, unspecified aspects of on-going CHMP discussions. So whether we should have a positive opinion on the development or request a re-examination remains unclear. 

On a different note I'd like to end this month's comment by introducing the new look PME. We've given our little facelift a lot of thought and, though you'll still find the same vital combination of accessible intelligence within its pages, I hope the design changes will make it that much easier on the eye.

I'd welcome your feedback on the changes – or, for that matter, any aspect of PME – and you can contact me via email on dtyer@pmlive.com.

Article by
Dominic Tyer

editorial director of PMGroup

17th February 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics